Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Feb 15, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today reported that it will host a Research & Development Day to highlight advance...
Feb 9, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be participating in the Leerink Partners 6th Annual...
Jan 5, 2017 SOUTH SAN FRANCISCO, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the appointment of Halley Gilbert, Senior Vice President and Chief Legal Office...
Dec 19, 2016 SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the completion of its previously announced underwritten public offering of 7,47...
Dec 14, 2016 SOUTH SAN FRANCISCO, Calif., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 6,500,000 shares of its common s...
Dec 12, 2016 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of up to 5,750,000 shares...
Dec 12, 2016 -- EPIC registration trial successfully achieves FDA primary endpoints in patients with complicated urinary tract infections (cUTI) -- -- EPIC demonstrates superiority on EMA primary endpoints -- -- CARE descriptive trial shows 71 percent relative reductio...
Dec 11, 2016 SOUTH SAN FRANCISCO, Calif., Dec. 11, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, will host a conference call and webcast tomorrow morning, December 12, 2016, at 8:30 a.m. EST. Man...
Nov 22, 2016 SOUTH SAN FRANCISCO, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on November 18, 2016, the compensation committee of the Company's board of di...
Nov 15, 2016 SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced the addition of Mr. Gary Loeb as General Counsel, effective today. Mr. Loeb will s...
Page:
1
... NextLast
= add release to Briefcase